Journal of Ocular Pharmacology and Therapeutics

Papers
(The H4-Index of Journal of Ocular Pharmacology and Therapeutics is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Matrix Metalloproteinases and Glaucoma Treatment69
The Immunological Basis of Dry Eye Disease and Current Topical Treatment Options68
Novel Ocular Drug Delivery Systems: An Update on Microemulsions57
Mucus-Penetrating Particles and the Role of Ocular Mucus as a Barrier to Micro- and Nanosuspensions45
Suprachoroidal Delivery of Viral and Nonviral Gene Therapy for Retinal Diseases37
Micelles: Promising Ocular Drug Carriers for Anterior and Posterior Segment Diseases36
Ophthalmic Drug Delivery Using Iontophoresis: Recent Clinical Applications32
Ophthalmic Applications of Cerium Oxide Nanoparticles28
Effects of the Selective EP2 Receptor Agonist Omidenepag on Adipocyte Differentiation in 3T3-L1 Cells27
Loteprednol Etabonate for the Treatment of Dry Eye Disease24
Influence of Perfluorohexyloctane Eye Drops on Tear Film Thickness in Patients with Mild to Moderate Dry Eye Disease: A Randomized Controlled Clinical Trial23
Eyes on Lipinski's Rule of Five: A New “Rule of Thumb” for Physicochemical Design Space of Ophthalmic Drugs21
Comprehensive Preclinical Assessment of ADVM-022, an Intravitreal Anti-VEGF Gene Therapy for the Treatment of Neovascular AMD and Diabetic Macular Edema20
Impact of Diquafosol Ophthalmic Solution on Tear Film and Dry Eye Symptom in Type 2 Diabetic Dry Eye: A Pilot Study18
Cationic Emulsion-Based Artificial Tears as a Mimic of Functional Healthy Tear Film for Restoration of Ocular Surface Homeostasis in Dry Eye Disease18
Transscleral Iontophoresis for Noninvasive Ocular Drug Delivery of Macromolecules18
The Antiglaucoma Agent and EP2 Receptor Agonist Omidenepag Does Not Affect Eyelash Growth in Mice17
A Randomized Double-Masked Phase 2a Trial to Evaluate Activity and Safety of Topical Ocular Reproxalap, a Novel RASP Inhibitor, in Dry Eye Disease17
0.027724027633667